证券代码：300254 证券简称：仟源医药 公告编号：2025-072 山西仟源医药集团股份有限公司 关于持股5%以上股东减持触及1%整数倍的公告 公司股东翁占国保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 山西仟源医药集团股份有限公司（以下简称"公司"或"本公司"）于2025 年10月22日披露了《关于持股5%以上股东减持股份的预披露公告》（公告编号： 2025-068）。翁占国先生持有公司股份15,772,409股，占公司总股本的6.16%。 其该公告披露之日起15个交易日后的3个月内以集中竞价和大宗交易的方式减持 公司股份不超过7,683,100股（占公司总股本比例不超过3%）。其中，以集中竞 价交易方式减持的，在任意连续90个自然日内减持股份的总数不超过公司总股本 的1%；以大宗交易方式减持的，在任意连续90个自然日内减持股份的总数不超过 公司总股本的2%。 公司于2025年11月19日收到公司持股5%以上股东翁占国先生出具的《关于股 份减持的告知函》，翁占国于2025年11月13日至2025年1 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | (万股/万份) | | | | | 2025-11-19 | 300254 | 任源医药 | 9.02 | 100.00 | | 902.00 国泰海通证券股份 | 国泰海通证券股份 | | | | | | | | 有限公司大同向阳 | 有限公司大同向阳 | | | | | | | | 街证券营业部 | 街证券营业部 | 11月19日，仟源医药大宗交易成交100万股，成交额902万元，占当日总成交额的7.07%，成交价9.02元，较市场收盘价10.91 元折价17.32%。 ...

Core Insights - In November, certain low-priced, high-recognition stocks have shown significant performance, with "Ma" stocks averaging a nearly 2% increase, surpassing the Shanghai Composite Index's performance during the same period, with multiple stocks rising over 10% [1] Group 1: Stock Characteristics - The analysis identifies 16 potential strong stocks for the year-end, focusing on those priced between 5 to 15 yuan per share and with a market capitalization below 5 billion yuan [1] - These stocks are predicted to have a net profit growth rate exceeding 30% for both 2025 and 2026, according to institutional consensus [1] - The companies involved are engaged in trending sectors such as quantum technology, AI, and lithium batteries [1] Group 2: Potential Stocks Summary - The table lists various stocks with their latest closing prices, market values, and projected net profit growth rates for 2025 and 2026, along with their associated hot concepts [2] - For instance, "Aoto Electronics" (002587) has a closing price of 6.42 yuan and a market value of 4.183 billion yuan, with a projected net profit growth of 193.43% for 2025 and 111.11% for 2026, focusing on Douyin Doubao [2] - "Liujin Technology" (920021) shows a closing price of 6.87 yuan and a market value of 2.123 billion yuan, with a projected net profit growth of 203.78% for 2025 and 96.00% for 2026, involved in 5G applications [2]

Core Viewpoint - QianYuan Pharmaceutical (300254.SZ) announced that its chairman and shareholder, Huang Lequn, plans to donate 200,000 shares to the Nanjing University Education Development Foundation, representing 0.08% of the company's total share capital [1] Group 1 - The shares for the donation will come from shares acquired in the secondary market and are all unrestricted circulating shares [1] - Huang Lequn's co-acting person, Zhao Qun, holds 15,781,792 shares, accounting for 6.16% of the total share capital, bringing their combined holdings to 21,246,852 shares, or 8.29% of the total [1] - This donation will not affect the company's compliance with listing conditions, as the largest shareholder remains Zhao Qun and Huang Lequn, and there will be no change in the actual controller or controlling shareholder of the company [1]

证券代码：300254 证券简称：仟源医药 公告编号：2025-071 山西仟源医药集团股份有限公司 关于股东对外捐赠的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、捐赠事项概述 为支持南京大学教育事业发展，山西仟源医药集团股份有限公司（以下简称 "公司"、"仟源医药"）董事长、股东黄乐群先生拟与南京大学教育发展基金 会（以下简称"南大基金会"）签署《捐赠协议书》，黄乐群先生拟向南大基金 会无偿捐赠20万股，占截至本公告日公司总股本的0.08%。本次捐赠的股份来源 于二级市场增持的股份，且均为无限售流通股。同时，黄乐群先生的一致行动人 赵群先生持股15,781,792股，占公司总股本的6.16%，黄乐群先生及其一致行动 人赵群先生合计持股21,246,852股，占公司总股本的8.29%。本次捐赠事宜不会导 致公司股权分布不符合上市条件，公司第一大股东仍为赵群先生及其一致行动人 黄乐群先生，公司仍无实际控制人和控股股东，不会导致公司实际控制人及控股 股东发生变化。 公司及股东黄乐群先生与南大基金会不存在关联关系，本次签署《捐赠协议》 不构成关联交易。 ...

证券代码：300254 证券简称：仟源医药 公告编号：2025-070 山西仟源医药集团股份有限公司 2025年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 10 月 29 日，山西仟源医药集团股份有限公司（以下简称"公司"） 召开了第五届董事会第三十五次会议，审议通过了《关于公司<2025 年第三季度 报告>的议案》。 为使投资者全面了解公司的经营成果、财务状况,公司《2025 年第三季度报 告》于 2025 年 10 月 30 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）披露，敬请广大投资者注意查阅。 特此公告 山西仟源医药集团股份有限公司 董事会 二○二五年十月三十日 ...

Group 1 - The core viewpoint of the article highlights that Q3 revenue for QianYuan Pharmaceutical reached 238 million yuan, representing a year-on-year increase of 14.82% [1] - The net profit for Q3 was 21.9466 million yuan, showing a significant year-on-year growth of 106.06% [1] - For the first three quarters, the total revenue amounted to 611 million yuan, which is a slight year-on-year increase of 0.44% [1] Group 2 - The net profit for the first three quarters was 22.3274 million yuan, indicating a year-on-year decline of 49.43% [1]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥238,477,452.79, representing a year-on-year increase of 14.82%[5] - Net profit attributable to shareholders was ¥21,946,557.84, a significant increase of 106.06% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,538,701.88, up 212.36% year-on-year[5] - The total operating revenue for the current period is ¥611,473,385.33, slightly up from ¥608,815,610.55 in the previous period, indicating a growth of approximately 0.27%[23] - Net profit for the current period was ¥48,470,797.18, down from ¥67,158,532.63, representing a decline of about 28%[25] - The total profit increased to ¥77,369,333.81 from ¥73,407,341.08, an increase of approximately 4.1%[24] - Basic earnings per share decreased to ¥0.0922 from ¥0.1827, a decline of about 49%[25] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,549,765,358.12, reflecting a slight increase of 0.13% from the end of the previous year[5] - Total assets amounted to ¥1,549,765,358.12, a slight increase from ¥1,547,725,078.17, indicating a growth of approximately 0.07%[21] - Total liabilities increased to ¥972,673,007.61 from ¥949,545,094.09, representing a rise of about 2.42%[21] - The company's equity attributable to shareholders decreased to ¥294,207,395.41 from ¥342,998,882.45, a decline of approximately 14.26%[21] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥75,411,853.86, an increase of 19.56% compared to the previous year[9] - Operating cash flow net amount increased to ¥75,411,853.86 from ¥63,071,990.33, an increase of approximately 19%[28] - Cash and cash equivalents decreased to ¥128,975,832.88 from ¥149,518,040.96, representing a decline of about 13.73%[19] - Cash and cash equivalents at the end of the period decreased to ¥128,964,832.88 from ¥176,467,322.01, a decline of about 27%[29] - Investment activities resulted in a net cash flow of -¥88,810,515.70, worsening from -¥59,371,258.67[28] - Financing activities generated a net cash flow of -¥7,143,546.24, compared to a positive cash flow of ¥40,774,022.37 in the previous period[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 24,916[11] - The top 10 shareholders hold a total of 56,000,000 shares, with Zhao Qun and Huang Lequn each holding 6.16% of the shares[11] - Zhao Qun has 15,781,792 shares, of which 11,836,344 are subject to lock-up restrictions[13] - The total number of restricted shares at the end of the reporting period is 30,424,393, with 9,439,925 shares added during the period[14] - The company has a stock incentive plan that allows for 25% of restricted shares to be unlocked annually starting in 2024[13] - The company held a board meeting to approve the 2025 stock incentive plan and related amendments[15] - The company has 204 core technical and key personnel with a total of 10,400,000 restricted shares under the incentive plan[14] - The top shareholder, Zhao Qun, has a total of 10,276,419 restricted shares at the beginning of the period[13] - The company has not disclosed any related party relationships among the top shareholders[11] Expenses and Costs - Financial expenses for the year-to-date were ¥17,522,800.00, an increase of 50.80% compared to the same period last year, mainly due to higher bank loan interest[9] - The company reported a decrease in other income by 62.88% year-on-year, amounting to ¥3,433,400.00, primarily due to reduced government subsidies received[9] - Total operating costs decreased from ¥563,187,725.70 to ¥552,167,468.27, a reduction of approximately 1.8%[24] - The company reported a tax expense of ¥28,898,536.63, significantly higher than ¥6,248,808.45 in the previous period[24] Other Information - The balance of construction in progress increased by 149.71% year-on-year, reaching ¥38,165,100.00, due to new factory renovation projects[8] - The balance of prepaid expenses increased by 51.33% year-on-year, totaling ¥4,323,600.00, primarily due to increased advance payments for goods[8] - The company's independent director Gao Hao resigned during the reporting period[15]

Group 1 - QianYuan Pharmaceutical (300254.SZ) experienced a decline of 3.91% in intraday trading, reaching a price of 10.57 yuan [2] - The company announced that a shareholder holding more than 5% of shares, Weng Zhangguo, plans to reduce his holdings by up to 7.6831 million shares, which represents no more than 3% of the company's total share capital [2]

Core Viewpoint - The shareholder Weng Zhangguo of Qianyuan Pharmaceutical plans to reduce his stake in the company by up to 7.6831 million shares, representing no more than 3% of the total share capital, through centralized bidding and block trading from November 13, 2025, to February 12, 2026 [1] Summary by Relevant Sections - Shareholder Reduction Plan - Weng Zhangguo intends to reduce his holdings by a maximum of 7.6831 million shares [1] - This reduction will account for up to 3% of the company's total share capital [1] - The planned timeframe for this reduction is from November 13, 2025, to February 12, 2026 [1]